Precision Oncology Market to Grow with a CAGR of 9.01% through 2029

Advancements in genomics and molecular biology is expected to drive the Global Precision Oncology Market growth in the forecast period, 2025-2029

 

According to TechSci Research report, “Precision Oncology Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Precision Oncology Market stood at USD 97.12 billion in 2023 and is anticipated to grow with a CAGR of 9.01% through 2029. 

Targeted therapies represent a significant advancement in cancer treatment, offering precise interventions that selectively block the abnormal molecular pathways fueling tumor growth. Companion diagnostics are integral to precision oncology, identifying patients who stand to benefit most from specific targeted therapies based on relevant biomarkers. The development of companion diagnostics alongside targeted therapies has accelerated the progress of personalized medicine, enhancing treatment outcomes and reducing unnecessary exposure to ineffective treatments and adverse effects.

The increasing global burden of cancer is a key factor driving the demand for precision oncology. With cancer incidence rising due to factors like aging populations, lifestyle shifts, and environmental influences, there is a pressing need for more efficient and personalized treatment options. Precision oncology holds promise in addressing cancer's complexity and diversity, tailoring treatments to each patient's unique genetic and molecular tumor profile. As cancer prevalence continues to climb worldwide, the demand for precision oncology is expected to rise accordingly.

While initially focused on specific cancer types with defined molecular targets, precision oncology is expanding to encompass a wider range of cancers. Advances in genomic profiling and biomarker discovery have paved the way for precision medicine applications in various cancer types, including rare and difficult-to-treat cancers. Furthermore, ongoing research aims to uncover the molecular basis of different malignancies, identifying new therapeutic targets and biomarkers that can guide precision oncology interventions. As precision oncology demonstrates effectiveness across diverse cancer types, its adoption is likely to increase among varied patient populations.

Advancements in genomics and molecular biology have transformed our ability to characterize tumors at the molecular level, pinpointing specific genetic alterations and biomarkers that inform treatment decisions. Technologies such as next-generation sequencing (NGS) enable comprehensive genomic profiling of tumors, facilitating the discovery of novel therapeutic targets and the development of targeted therapies.

 The utilization of genomic profiling and molecular diagnostics is experiencing a significant uptrend in precision oncology. Technologies like next-generation sequencing (NGS) enable the detection of genetic alterations and biomarkers linked to cancer. These molecular diagnostic tools offer valuable insights into tumor molecular characteristics, aiding in personalized treatment decisions. The market trend underscores the rising demand for genomic profiling and molecular diagnostics to inform targeted therapies in cancer patients.

Targeted therapies are gaining traction in precision oncology, focusing on specific genetic or molecular abnormalities in cancer cells. They offer enhanced treatment outcomes and reduced side effects compared to traditional chemotherapy. Identifying actionable mutations through genomic profiling enables the selection of targeted therapies tailored to each patient's tumor profile. The market trend highlights the increasing interest in targeted therapies and the necessity for precision medicine approaches in cancer treatment. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Precision Oncology Market”

The Global Precision Oncology Market is segmented into product type, cancer type, end user, regional distribution, and company.

Based on the product type, therapeutics segment emerged as the dominant segment in the global precision oncology market in 2023. In recent years, targeted therapies have experienced significant advancements, leading to their widespread adoption in precision oncology. These therapies exploit precise genetic or molecular alterations found in cancer cells, such as mutations, amplifications, or fusion genes. By targeting these alterations, targeted therapies can disrupt critical signaling pathways involved in cancer growth and progression. The development of targeted therapies has broadened the treatment options available for various cancers, expanding the scope of precision oncology therapeutics.

Precision oncology revolves around customizing treatments to individual patients based on their distinct molecular profiles. Therapeutics play a pivotal role in this personalized treatment approach. Through the analysis of genomic data obtained via molecular diagnostics, healthcare providers can pinpoint specific genetic alterations propelling the growth of a patient's tumor. Therapeutics are then selected to address these alterations, thereby enhancing treatment effectiveness and minimizing potential side effects. The ability to deliver personalized treatment regimens is a key driver for the dominance of the therapeutics segment in precision oncology.

North America emerged as the dominant player in the global precision oncology market in 2023, holding the largest market share. North America harbors a sizable and varied patient demographic, comprising a substantial portion of individuals with cancer who can potentially gain from precision oncology methods. The region's elevated cancer incidence rates, along with increasing acknowledgment and endorsement of personalized medicine, have spurred the requirement for precision oncology solutions among patients, healthcare practitioners, and payers. Moreover, favorable regulatory measures and reimbursement structures in North America have streamlined the commercialization and uptake of precision oncology offerings.

Major companies operating in Global Precision Oncology Market are:

• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Qiagen N.V.
• Illumina, Inc.
• Laboratory Corporation Of America Holding
• Exact Sciences Corporation
• Rain Oncology Inc.
• Strata Oncology, Inc.
• Xilis Inc.
• Variantyx, Inc

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Global Precision Oncology Market is poised for significant growth in the coming years. Advancements in genomics and molecular biology are enabling a deeper understanding of cancer at the molecular level, facilitating the development of targeted therapies and companion diagnostics. Additionally, the rise of immunotherapy and the expansion of liquid biopsies offer new avenues for personalized cancer treatment. Growing cancer prevalence worldwide, coupled with increasing awareness and acceptance of precision medicine, further fuel market growth. Moreover, the integration of artificial intelligence and big data analytics enhances the interpretation of complex genomic data, driving innovation and improving treatment outcomes.” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Precision Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Diagnostics, Therapeutics), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer), By End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies) Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Precision Oncology Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Precision Oncology Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com